Rs.4,254cr invested in manufacturing drugs
Forty-eight projects have been approved under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India.
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on single source, Minister of State for Chemicals and Fertilizers Anupriya Patel updated Rajya Sabha in a written reply on 22 July https://chemicals.gov.in/.
Products notified and approved under the scheme prior to commencement of production under the PLI scheme were primarily imported.
As of December 2024, investment of Rs.4,254 crore has been made under the scheme against a commitment of Rs.3,938.5 crore over past six years. As a result of the scheme, cumulative sales of Rs.1,556 crore have been reported over the period from the beginning of the scheme till December 2024, including exports of Rs.412 crore, thereby avoiding imports worth Rs.1,144 crore and creating domestic manufacturing capacity for 25 identified KSMs/DIs/APIs https://www.makeinindia.com/home/.
A number of measures were taken to enhance awareness and encourage participation in the scheme at the time of the launch of the scheme and various rounds of invitation of applications under it, including the following:
Conducting of webinars and stakeholder consultation meetings with industry associations and potential applicants https://www.bseindia.com/;
Issuing of press releases, detailed guidelines, clarifications in the form of frequently asked questions (FAQs) and answers thereto and scheme notifications on official websites https://www.nseindia.com/;
Regular outreach through social media campaigns;
Provision of dedicated helpdesk support and query resolution mechanisms through the scheme portal. Fiinews.com
